1) Baxter EJ, Scott LM, Campbell PJ, et al:Acquired mutation of the thyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061,2005
2) James C, Ugo V, Le Couedic JP, et al:A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148,2005
3) Kralovics R, Passamonti F, Buser AS, et al:A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790,2005
4) Levine RL, Wadleigh M, Cools J, et al:Activating mutation in the thyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397,2005
5) Jones AV, Kreil S, Zoi K, et al:Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162-2168,2005
6) Saharinen P, Vihinen M, Silvennoinen O:Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 14:1448-1459,2003
7) Kaushansky K:On the molecular origins of the chronic myeloproliferative disorders:it all makes sense. Hematology Am Soc Hematol Educ Program:533-537,2005
8) 臼杵憲祐:本態性血小板血症の病態と治療.日内会誌 96:62-69,2007
9) Tefferi A, Lasho TL, Schwager SM, et al:The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106:631-635,2006
10) Campbell PJ, Baxter EJ, Beer PA, et al:Mutation of JAK2 in the myeloproliferative disorders:timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108:3548-3555,2006